TechNVision Ventures Ltd Share Price – BSE

IT - Software, Small Cap

Solix Technologies (an affiliate of TechNVision Ventures) announced the signing of a Memorandum of Understanding (MoU) with Symbiosis Center for Entrepreneurship & Innovation (SCE) in collaboration with Symbiosis Medical College for Women (SMCW,), to establish a Center of Excellence (CoE) in New Drug Development and Drug Repurposing.

The MoU was formalized during TAL HealthFest 2026, reinforcing the commitment of both institutions to advance innovation at the intersection of Artificial Intelligence, biomedical research, and translational medicine.

The Center of Excellence aims to integrate:

• Computational intelligence and Al-driven in-silico modeling
• Molecular validation frameworks
• In-vivo translational research

The initial focus areas will include:

• Alzheimer's disease
• PAMR (Priority Antimicrobial Resistant) pathogens

This collaboration brings together Solix's 25+ years of expertise in end-to-end data lifecycle management, governance, and Enterprise Al with SMCW's clinical, translational, and biomedical research strengths.

Powered by Capital Market - Live News

Net profit of TechNVision Ventures rose 172.79% to Rs 3.71 crore in the quarter ended December 2025 as against Rs 1.36 crore during the previous quarter ended December 2024. Sales declined 8.13% to Rs 74.38 crore in the quarter ended December 2025 as against Rs 80.96 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

TechNVision Ventures will hold a meeting of the Board of Directors of the Company on 13 February 2026.

Powered by Capital Market - Live News

Net profit of TechNVision Ventures reported to Rs 0.71 crore in the quarter ended September 2025 as against net loss of Rs 2.58 crore during the previous quarter ended September 2024. Sales rose 29.30% to Rs 71.23 crore in the quarter ended September 2025 as against Rs 55.09 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News